State coverage

Nebraska Medicaid and GLP-1 coverage

State Medicaid · 4 documents cited

Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.

At a glance

Other diagnoses only

Medicaid, for obesity: Both drugs are off the standard list, each with its own pathway: Wegovy for heart risk, Zepbound for sleep apnea.

Appeal deadline: 60 days from the date on your denial notice to appeal to your health plan, then 120 days from that plan's decision to ask for a state fair hearing source

Primary source: Nebraska Department of Health and Human Services, Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Date read: September 2026

American GLP, Publisher · Who writes this site

Nebraska's standard Preferred Drug List handles GLP-1s strictly as diabetes drugs. Its diabetic GLP-1 class covers Ozempic, Trulicity and Victoza as preferred agents and Mounjaro, Rybelsus and Bydureon BCise as non-preferred, each gated behind a documented type 2 diabetes diagnosis. Wegovy, Zepbound and Saxenda do not appear anywhere in the 97-page list, under any heading. Read alone, that would look like a flat exclusion.

It is not the whole picture. Nebraska Medicaid runs two separate, drug-specific prior authorization forms for exactly these two products, entirely outside the standard drug-list process. The Wegovy form states its own scope on the first page: coverage for reducing cardiovascular risk in adults 45 to 74, or for treating a liver condition called MASH. No box on the form exists for a weight-loss-only request. The Zepbound form is narrower still and says so bluntly: tirzepatide is covered only for moderate-to-severe obstructive sleep apnea, and only after documented failure or intolerance of CPAP therapy.

The age band on the Wegovy pathway — 45 to 74 — is unusual; most states writing a cardiovascular-risk carve-out for these drugs set no upper age bound at all. Nebraska's form does not explain the ceiling, and nothing else read here does either.

One limit is worth stating plainly, because it is about our sources rather than about Nebraska. The appeal deadline below is quoted from the state's own Heritage Health program page, addressed to the reader and giving DHHS's own filing address, rather than from the administrative code chapter that presumably sets it. That chapter, 482 NAC ch. 7, could not be located on a Nebraska government host on 2026-09-03. The figures below are the ones the state publishes to members; they were not checked against the regulation's own text.

What we could verify for Nebraska

The state's drug list files these drugs under "HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS," in a class headed "GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA)." Ozempic, Trulicity and Victoza are preferred; Bydureon BCISE, Byetta, generic exenatide and liraglutide, Mounjaro and Rybelsus are non-preferred. The criteria read: "Preferred agents require a diagnosis of Type II diabetes AND a trial and failure or intolerance to metformin OR A diagnosis of ASCVD associated with a diagnosis of Type II diabetes," and a non-preferred agent needs a failed trial of two preferred agents first. Neither Wegovy, Zepbound nor Saxenda is named anywhere in this 97-page document, under this or any other heading.

Nebraska Department of Health and Human Services, Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria, effective January 2026 · source

Nebraska's drug-specific prior authorization form states its scope on page one: "Semaglutide (Wegovy) is covered for the reduction of the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults 45 to 74 years of age, or for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults at least 18 years of age." The cardiovascular pathway also requires either "An initial BMI of at least 27 kg/m2 and at least one weight-related comorbid condition" or "An initial BMI of at least 30 kg/m2," plus six months of a physician-supervised weight-management program before initial approval.

Nebraska Department of Health and Human Services, Nebraska Medicaid Fee-For-Service Pharmacy Benefit, Request for Prior Authorization — Wegovy (semaglutide), effective January 2026 · source

Nebraska's Zepbound-specific form is more restrictive and says so directly: "Tirzepatide (Zepbound) is only covered for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults aged at least 18 years." Initial approval requires an initial BMI of at least 30, six months of a supervised weight-management program including "Counseling to avoid sleeping in the supine position" and "Counseling to avoid alcohol and sedatives before bedtime," and documentation that the member has been treated with positive airway pressure therapy and either failed to reach therapeutic goals on it or could not tolerate it.

Nebraska Medicaid Program, Request for Prior Authorization — Anti-Obesity Medication (Zepbound/tirzepatide), effective July 2025 · source

Nebraska's Heritage Health program states two appeal clocks: "You have sixty (60) days from the date on your notice of adverse benefit determination to request an appeal with your health plan... You have 120 days from the date on the notice of resolution for the health plan appeal to request a State Fair Hearing." Requests for a state fair hearing go in writing to "Department of Health and Human Services, MLTC Appeal Coordinator, PO Box 94967, Lincoln, NE 68509-4967."

Nebraska Department of Health and Human Services, Heritage Health program · source

Nebraska is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Nebraska Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Nebraska with the rest in the coverage matrix.

If you work for the State of Nebraska

State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State of Nebraska employee health plans (Blue Cross and Blue Shield of Nebraska from July 1, 2026). Its pharmacy benefit runs through Prime Therapeutics, retained by Blue Cross and Blue Shield of Nebraska.

Weight loss drugs excluded

Nebraska's 2026-27 state employee plans don't cover diet or weight loss drugs, or obesity treatment in general. The 2025-26 plan went further and excluded any drug with a weight loss approval for every condition.

Among the services not covered under the prescription drug program: "diet, weight loss or appetite suppressant drugs (Anorexics), dietary and herbal or nutritional supplements"

Nebraska DAS / Blue Cross and Blue Shield of Nebraska, A Guide to Your Health Benefits, State of Nebraska $1,400 Deductible (Regular) Plan, effective July 2026 · source

The medical exclusions add "treatment and monitoring for obesity or weight reduction, regardless of diagnosis."

Nebraska DAS / Blue Cross and Blue Shield of Nebraska, A Guide to Your Health Benefits, State of Nebraska $1,400 Deductible (Regular) Plan, effective July 2026 · source

"Prime Therapeutics, LLC, (Prime) has been retained by BCBSNE to administer the Rx Nebraska Prescription Drug Program."

Nebraska DAS / Blue Cross and Blue Shield of Nebraska, A Guide to Your Health Benefits, State of Nebraska $1,400 Deductible (Regular) Plan, effective July 2026 · source

The Consumer Focused high-deductible plan has the same drug exclusion: "diet, weight loss or appetite suppressant drugs (Anorexics)"

Nebraska DAS / Blue Cross and Blue Shield of Nebraska, A Guide to Your Health Benefits, State of Nebraska $3,400 Deductible (Consumer Focused) Plan, effective July 2026 · source

Under the 2025-26 UnitedHealthcare plan, "A drug with an FDA-approved indication for weight loss (such as a GLP-1 or dual GLP-1/GIP agonist) is not covered for any condition, including other FDA-approved indications"

State of Nebraska / UnitedHealthcare, Summary Plan Description, Regular Plan (Effective July 1, 2025), effective July 2025 · source

If the appeal fails, or you cannot wait

Nebraska Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.

These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.

Companies that pay this site a commission, what we found on each one's own site, and a link to check availability
Company	What we found on its own site
PartnerFoundCheck availability	Bills clinician visits to your insurance where it's in network, with the drug charged separately. Its Medicare offer, brand GLP-1s from $50 a month, doesn't count toward your Part D deductible or out-of-pocket maximum, and Extra Help doesn't apply.
PartnerEdenCheck availability	Semaglutide at $99 a month at every dose, with no membership on the page our link opens. Eden's own site pairs the same $99 with a required membership ($39 the first month, then $99), so check which one you're signing up for.
PartnerShedRxCheck availability	Injections plus needle-free drops and lozenges. You see a price only after the questionnaire, and the oral forms aren't sold in sixteen states.
PartnerHealthRXCheck availability	Compounded semaglutide at $133 a month on a three-month plan ($99 on twelve), tirzepatide from $209 ($179 on twelve). Its member reviews are labeled illustrative composites, not real patients.
PartnerMEDGmCheck availability	GLP-1 injections from $179 and tablets from $249. Brand options are a membership plus the drug's own cost: $99 for Zepbound or Wegovy, $171 for Ozempic. It discloses AI content and actor imagery.
PartnerBodybuilding Health+Check availability	Compounded tirzepatide at $174.67 to $209 a month, lower the more months you buy at once; semaglutide is tiered the same way. Operated by Dynamo Group LLC.

All 21 companies, with what we found on each →

Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.

Where this comes from

Nebraska Department of Health and Human Services, Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria, effective January 2026 — Open the document
Nebraska Department of Health and Human Services, Nebraska Medicaid Fee-For-Service Pharmacy Benefit, Request for Prior Authorization — Wegovy (semaglutide), effective January 2026 — Open the document
Nebraska Medicaid Program, Request for Prior Authorization — Anti-Obesity Medication (Zepbound/tirzepatide), effective July 2025 — Open the document
Nebraska Department of Health and Human Services, Heritage Health program — Open the document